Pharmaceutical Preparations · DE · CIK 1534120
Developing IL-1β-based treatments for immune-mediated inflammatory diseases, including their lead candidate abdakibart for hidradenitis suppurativa
Comparable business profile · signals at a glance
In the 90 days to Mar 16, 2026: 1 sold $412K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Doyle MittieChief Medical Officer | Sell | 25,492 | $16.15 | $412K |
| Nov 14, 2025 | Goldman JonathanDirector | Sell | 8,200 | $14.35 | $118K |
| Nov 14, 2025 | Goldman JonathanDirector | Sell | 3,167 | $14.30 | $45K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.